Sydney-based cancer drug development company PacMab has lodged a prospectus for an IPO to raise AUD$5 million to commercialise its treatment for a fatal blood cancer and potentially other blood disorders, with listing of its shares on the ASX expected in December this year.

Sydney monoclonal antibody therapeutics developer PacMab - which this week raised AUD$700,000 in equity funding -- is in the late stages of clinical pre-testing of a humanised monoclonal antibodies that binds to an antigen expressed exclusively by multiple myeloma cells.